Loading...
OTCM
RAFA
Market cap8mUSD
Jul 17, Last price  
0.08USD
1D
0.00%
1Q
3.45%
Jan 2017
1,700.00%
IPO
-18.18%
Name

Rafarma Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
0.00
Div Yield, %
Shrs. gr., 5y
0.91%
Rev. gr., 5y
133.12%
Revenues
10m
-84.24%
00125,098147,20311,441,55774,730,00077,411,00064,313,99910,135,000
Net income
273k
-94.50%
0-14,845-97,068-6,1793,053,60814,848,00011,573,0004,961,000273,000
CFO
-51m
L
0-1,000105,865-75,39310,210,418-8,762,0002,877,00018,769,000-50,671,000

Profile

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
IPO date
Jul 11, 2001
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122020‑012019‑012018‑01
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT